A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Phase 1

Phase 2

A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)

Sponsor:

Editas Medicine, Inc.

Code:

NCT04853576

Conditions

Sickle Cell Disease

Hemoglobinopathies

Eligibility Criteria

Sex: All

Age: 12 - 50

Healthy Volunteers: Not accepted

Interventions

EDIT-301

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information